Sangamo Therapeutics, Inc. (SGMO) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -19.28M | -24.4M | -28.5M | -18.16M | -26.15M | -3.35M | 11.76M | -26.88M | -48.66M | -50.54M | -47.29M | -60.71M |
| Operating CF Margin % | -1337.17% | -171.51% | -4904.99% | -99.19% | -406.23% | -44.38% | 23.8% | -7551.69% | -10117.05% | -2474.93% | -503.22% | -888.24% |
| Operating CF Growth % | 26.26% | -628.23% | -342.35% | 32.46% | 46.27% | 93.37% | 124.86% | 55.72% | 26.6% | 11.41% | 11.8% | -12.46% |
| Net Income | -31M | -37.42M | -34.93M | -19.99M | -30.6M | -23.4M | 10.67M | -36.13M | -49.09M | -60.3M | -104.16M | -114.51M |
| Depreciation & Amortization | 877K | 1.88M | 1.9M | 1.9M | 1.92M | 2.13M | 2.13M | 2.57M | 2.53M | 3.01M | 7.42M | 6.18M |
| Stock-Based Compensation | 992K | 2.13M | 2.13M | 2.23M | 2.6M | 3.28M | 3.31M | 3.06M | 2.72M | 6.11M | 6.19M | 6.79M |
| Deferred Taxes | 0 | 0 | 0 | -15K | 15K | -18K | 18K | 0 | 0 | -140K | 182K | 0 |
| Other Non-Cash Items | 0 | 13.23M | 0 | 45K | -10K | -692K | 99K | 1.07M | 4.08M | -2K | 45.75M | 44.15M |
| Working Capital Changes | 9.84M | -4.23M | 2.41M | -2.33M | -77K | 15.34M | -4.47M | 2.54M | -8.89M | 783K | -2.67M | -3.33M |
| Change in Receivables | 4.02M | 152K | -151K | -6K | 160K | 10.12M | -9.88M | 3M | -1.16M | 425K | 1.57M | 4.11M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.12M | 0 |
| Change in Payables | 4.94M | -1.51M | 4M | -3.92M | 4.22M | -7.32M | -2.2M | 0 | -4.94M | 10.81M | -2.12M | -1.2M |
| Cash from Investing | -13K | -14K | -64K | -24K | 0 | 1.32M | 233K | 127K | 35.84M | 37.71M | 37.63M | 42.47M |
| Capital Expenditures | -13K | -14K | -64K | -24K | 0 | -152K | -115K | 0 | 0 | -2.67M | -2.74M | -5.54M |
| CapEx % of Revenue | 0.9% | 0.1% | 11.02% | 0.13% | - | 2.01% | 0.23% | - | - | 130.8% | 29.2% | 81.05% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40.37M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 1.48M | 348K | 127K | 0 | 0 | 40.37M | 0 |
| Cash from Financing | 26.7M | 14.8M | 19.2M | 28.61M | 8.13M | 6.99M | -203K | -533K | 22.12M | 167K | -100K | 6.52M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 27.08M | 15.15M | 19.47M | 29.03M | 10.36M | 7.07M | 0 | -600K | 22.52M | -719K | 1K | 5.99M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -379K | -349K | -267K | -420K | -2.23M | -76K | -203K | 67K | -402K | 886K | -101K | 525K |
| Net Change in Cash | 6.64M | -9.58M | -7.82M | 13.16M | -16.74M | 2.72M | 12.91M | -27.55M | 8.63M | -11.31M | -10.32M | -11.41M |
| Free Cash Flow | -19.3M | -24.42M | -28.56M | -18.18M | -26.15M | -3.5M | 11.64M | -26.88M | -48.66M | -53.21M | -50.04M | -66.25M |
| FCF Margin % | -1338.07% | -171.61% | -4916.01% | -99.32% | -406.23% | -46.39% | 23.57% | -7551.69% | -10117.05% | -2605.73% | -532.42% | -969.29% |
| FCF Growth % | 26.21% | -597.03% | -345.29% | 32.37% | 46.27% | 93.42% | 123.27% | 59.42% | 36.39% | 17.53% | 13.78% | -11.48% |
| FCF per Share | -0.05 | -0.07 | -0.09 | -0.07 | -0.12 | -0.02 | 0.05 | -0.13 | -0.27 | -0.30 | -0.28 | -0.38 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.65x | 0.82x | 0.91x | 0.85x | 0.14x | 1.10x | 0.74x | 0.99x | 0.84x | 0.45x | 0.53x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |